 Shares of Eiger BioPharmaceuticals Inc. EIGR, -1.20 tumbled 20.4 in premarket trading on Wednesday after the company said it will not pursue emergency authorization of its experimental treatment for mild and moderate COVID-19 infections. It had asked the Food and Drug Administration to consider an EUA application based on data from the Together trial, a Phase 3 study that has assessed 11 possible treatments for COVID-19 that is being conducted in Brazil and Canada. 